Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancerhttps://www.nct-dresden.de/en/trials/900-000002473https://www.nct-dresden.de/@@site-logo/logo-nct.svg
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer
Urogenital tumors
Prostatakarzinom
other systemic therapies
The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).
The main objective of the study is to compare overall survival in participants receivingxaluritamig versus investigator's choice (cabazitaxel or second androgenreceptor-directed therapy [ARDT]).
